Is Vaxcyte Stock a Good Investment?
Vaxcyte Investment Advice | PCVX |
- Examine Vaxcyte's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vaxcyte's leadership team and their track record. Good management can help Vaxcyte navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vaxcyte's business and its evolving consumer preferences.
- Compare Vaxcyte's performance and market position to its competitors. Analyze how Vaxcyte is positioned in terms of product offerings, innovation, and market share.
- Check if Vaxcyte pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vaxcyte's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vaxcyte stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vaxcyte is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Vaxcyte Stock
Researching Vaxcyte's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Vaxcyte recorded a loss per share of 3.99. The entity had not issued any dividends in recent years.
To determine if Vaxcyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vaxcyte's research are outlined below:
| Vaxcyte had very high historical volatility over the last 90 days | |
| Net Loss for the year was (463.93 M) with loss before overhead, payroll, taxes, and interest of (75 M). | |
| Vaxcyte currently holds about 354.5 M in cash with (452.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98. | |
| Vaxcyte has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Mizuho Maintains an Overweight Rating on Vaxcyte |
Vaxcyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vaxcyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaxcyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vaxcyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vaxcyte's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-11 | 2021-06-30 | -0.52 | -0.46 | 0.06 | 11 | ||
2021-05-11 | 2021-03-31 | -0.48 | -0.41 | 0.07 | 14 | ||
2022-11-07 | 2022-09-30 | -0.84 | -0.93 | -0.09 | 10 | ||
2022-08-08 | 2022-06-30 | -0.69 | -0.8 | -0.11 | 15 | ||
2024-08-06 | 2024-06-30 | -0.98 | -1.1 | -0.12 | 12 | ||
2023-05-08 | 2023-03-31 | -0.83 | -0.7 | 0.13 | 15 | ||
2021-03-29 | 2020-12-31 | -0.54 | -0.41 | 0.13 | 24 | ||
2024-11-04 | 2024-09-30 | -1.13 | -0.83 | 0.3 | 26 |
Vaxcyte Target Price Consensus
Vaxcyte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Vaxcyte's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Vaxcyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Vaxcyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Vaxcyte, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVaxcyte Target Price Projection
Vaxcyte's current and average target prices are 36.21 and 125.75, respectively. The current price of Vaxcyte is the price at which Vaxcyte is currently trading. On the other hand, Vaxcyte's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Vaxcyte Target Price
Vaxcyte Analyst Ratings
Vaxcyte's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Vaxcyte stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Vaxcyte's financials, market performance, and future outlook by experienced professionals. Vaxcyte's historical ratings below, therefore, can serve as a valuable tool for investors.Know Vaxcyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxcyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxcyte backward and forwards among themselves. Vaxcyte's institutional investor refers to the entity that pools money to purchase Vaxcyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-03-31 | 2.9 M | T. Rowe Price Investment Management,inc. | 2025-03-31 | 2.7 M | Westfield Capital Management Company, L.p. | 2025-03-31 | 2.2 M | Jpmorgan Chase & Co | 2025-03-31 | 1.9 M | Alliancebernstein L.p. | 2025-03-31 | 1.7 M | Paradigm Biocapital Advisors Lp | 2025-03-31 | 1.7 M | Commodore Capital Lp | 2025-03-31 | 1.6 M | Charles Schwab Investment Management Inc | 2025-03-31 | 1.3 M | Amvescap Plc. | 2025-03-31 | 1.3 M | Fmr Inc | 2025-03-31 | 12.5 M | Ra Capital Management, Llc | 2025-03-31 | 12.2 M |
Vaxcyte's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.67 B.Market Cap |
|
Vaxcyte's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.14) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.15) |
Determining Vaxcyte's profitability involves analyzing its financial statements and using various financial metrics to determine if Vaxcyte is a good buy. For example, gross profit margin measures Vaxcyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vaxcyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Vaxcyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxcyte. Check Vaxcyte's Beneish M Score to see the likelihood of Vaxcyte's management manipulating its earnings.
Evaluate Vaxcyte's management efficiency
Vaxcyte has return on total asset (ROA) of (0.1453) % which means that it has lost $0.1453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1966) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.14 in 2025. Return On Capital Employed is likely to drop to -0.18 in 2025. At this time, Vaxcyte's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 1.2 B in 2025, whereas Other Assets are likely to drop 1.09 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 27.10 | 28.45 | |
| Tangible Book Value Per Share | 27.10 | 28.45 | |
| Enterprise Value Over EBITDA | (21.58) | (20.50) | |
| Price Book Value Ratio | 3.02 | 1.82 | |
| Enterprise Value Multiple | (21.58) | (20.50) | |
| Price Fair Value | 3.02 | 1.82 | |
| Enterprise Value | 8.7 B | 7.7 B |
The leadership approach at Vaxcyte's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.204 |
Basic technical analysis of Vaxcyte Stock
As of the 20th of July, Vaxcyte has the Coefficient Of Variation of 1543.77, semi deviation of 3.65, and Risk Adjusted Performance of 0.0683. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vaxcyte, as well as the relationship between them.Vaxcyte's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxcyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxcyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaxcyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaxcyte's Outstanding Corporate Bonds
Vaxcyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vaxcyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vaxcyte bonds can be classified according to their maturity, which is the date when Vaxcyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Vaxcyte's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vaxcyte's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0683 | |||
| Market Risk Adjusted Performance | 0.1719 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 3.65 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 1543.77 | |||
| Standard Deviation | 4.22 | |||
| Variance | 17.77 | |||
| Information Ratio | 0.0314 | |||
| Jensen Alpha | 0.0505 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0349 | |||
| Treynor Ratio | 0.1619 | |||
| Maximum Drawdown | 21.28 | |||
| Value At Risk | (4.87) | |||
| Potential Upside | 6.93 | |||
| Downside Variance | 14.4 | |||
| Semi Variance | 13.32 | |||
| Expected Short fall | (3.73) | |||
| Skewness | 0.0587 | |||
| Kurtosis | 2.77 |
| Risk Adjusted Performance | 0.0683 | |||
| Market Risk Adjusted Performance | 0.1719 | |||
| Mean Deviation | 3.04 | |||
| Semi Deviation | 3.65 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 1543.77 | |||
| Standard Deviation | 4.22 | |||
| Variance | 17.77 | |||
| Information Ratio | 0.0314 | |||
| Jensen Alpha | 0.0505 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0349 | |||
| Treynor Ratio | 0.1619 | |||
| Maximum Drawdown | 21.28 | |||
| Value At Risk | (4.87) | |||
| Potential Upside | 6.93 | |||
| Downside Variance | 14.4 | |||
| Semi Variance | 13.32 | |||
| Expected Short fall | (3.73) | |||
| Skewness | 0.0587 | |||
| Kurtosis | 2.77 |
Consider Vaxcyte's intraday indicators
Vaxcyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vaxcyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Vaxcyte Corporate Filings
8K | 17th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 15th of May 2025 Other Reports | ViewVerify | |
F3 | 2nd of May 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Vaxcyte Stock media impact
There is far too much social signal, news, headlines, and media speculation about Vaxcyte that are available to investors today. This information is accessible both publicly - through Vaxcyte's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Vaxcyte-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Vaxcyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxcyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxcyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxcyte alpha.
Vaxcyte Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vaxcyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vaxcyte Historical Investor Sentiment
Investor biases related to Vaxcyte's public news can be used to forecast risks associated with an investment in Vaxcyte. The trend in average sentiment can be used to explain how an investor holding Vaxcyte can time the market purely based on public headlines and social activities around Vaxcyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vaxcyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vaxcyte and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Vaxcyte news discussions. The higher the estimate score, the more favorable the investor's outlook on Vaxcyte.
Vaxcyte Maximum Pain Price Across October 17th 2025 Option Contracts
Vaxcyte's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Vaxcyte close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Vaxcyte's options.
Vaxcyte Corporate Management
| Mikhail JD | General VP | Profile | |
| Karen Alderete | Ex HR | Profile | |
| Whitney Jones | Chief Officer | Profile | |
| Ashish MBA | CoFounder Officer | Profile | |
| Jeff Fairman | CoFounder Research | Profile | |
| Mark MBA | Chief Officer | Profile |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.